Biotech Archives - Page 695 of 733

1 minute read

Gilead Shares Climb On Positive Interim Analysis From Late-Stage Breast Cancer Study

August 15, 10:17 AM

Gilead Sciences, Inc. (NASDAQ: GILD) announced positive results from the second interim analysis of the key secondary endpoint of overall survival (OS) in the Phase 3 TROPiCS-02 study evaluating Trodelvy (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer.

GILD

1 minute read

BrainStorm To File US Application For NurOwn In Amyotrophic Lateral Sclerosis

By Vandana Singh

August 15, 9:49 AM

BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) announced its decision to submit a marketing application to the FDA seeking approval for NurOwn for…

BCLI

1 minute read

Anixa Initiates Patient Dosing in Initial-Stage Ovarian Cancer Study

By Ragothaman Srinivasan

August 15, 9:47 AM

Anixa Biosciences (NASDAQ: ANIX) commenced treatment of the first patient in the clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.

ANIX

1 minute read

Novavax Seeks FDA Emergency Use Nod For Its COVID-19 Vaccine Booster

By Vandana Singh

August 15, 9:28 AM

Novavax Inc (NASDAQ:NVAX) has submitted an application to the FDA for Emergency Use Authorization (EUA) for its protein-based COVID-19 vaccine as…

NVAX

1 minute read

Clene Shares Fall Despite Multiple Sclerosis Candidate Showing Neurological Improvements

By Vandana Singh

August 15, 9:04 AM

Clene Inc (NASDAQ:CLNN) has announced topline results from the Phase 2 VISIONARY-MS trial of CNM-Au, an investigational gold nanocrystal suspension, in…

CLNN

2 minute read

Gilead Sciences Announces Trodelvy Significantly Improves Overall Survival In Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients In The TROPiCS-02 Study

By Benzinga Newsdesk

August 15, 8:42 AM

Gilead Sciences, Inc. (NASDAQ:GILD) today announced statistically significant and clinically meaningful results from the second interim analysis of the key secondary endpoint of overall survival (OS) in the Phase 3

GILD

1 minute read

Virios Therapeutics Commences Mid-Stage Long-COVID Study

By Ragothaman Srinivasan

August 15, 8:27 AM

Virios Therapeutics (Nasdaq: VIRI) has initiated patient dosing in its exploratory Long-COVID trial evaluating IMC-2 (valacyclovir + celecoxib).

VIRI

2 minute read

Amarin Corporation Announces Research Evaluating VASCEPA/VAZKEPA And Subgroups From The REDUCE-IT Landmark Outcomes Trial To Be Presented At The European Society Of Cardiology Congress

By Benzinga Newsdesk

August 15, 8:02 AM

Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded research on the effects of VASCEPA®/VAZKEPA (icosapent ethyl) in specific patient subgroups at increased risk of a cardiovascular (CV)

AMRN

2 minute read

BD, Accelerate Diagnostics Announce Global Commercial Collaboration

By Benzinga Newsdesk

August 15, 6:52 AM

BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, and Accelerate Diagnostics, Inc. (NASDAQ:AXDX) an innovator of rapid in-vitro diagnostics in microbiology, today announced a

AXDX